The one step will be an outcome one way or another in the litigation against the Jublia patents, which from an ACR perspective has been settled (ASX announcement Sep 18) with Valeant Pharmaceuticals (subsidiary of Bausch) but there must be other companies still fighting the patents.
Looking at Bausch's website it has Global sales of Jublia at circa USD 100mil
In order for any of ACR's generics to get FDA approval they need to be exactly the same as the Brand in every-way, including, method of treatment.
ACR Price at posting:
18.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)